Anderson J - Search Results

1

Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis.

Tabák ÁG, Anderson J, Aschner P, Liu M, Saremi A, Stella P, Tinahones FJ, Wysham C, Meier JJ. Tabák ÁG, et al. Among authors: anderson j. Diabetes Ther. 2020 Jan;11(1):305-318. doi: 10.1007/s13300-019-00735-7. Epub 2019 Dec 17. Diabetes Ther. 2020. PMID: 31848983 Free PMC article.

2

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

Anderson JE, Wright EE Jr, Shaefer CF Jr. Anderson JE, et al. Diabetes Ther. 2017 Feb;8(1):33-53. doi: 10.1007/s13300-016-0211-x. Epub 2016 Nov 11. Diabetes Ther. 2017. PMID: 27837465 Free PMC article. Review.

3

The Impact of Web-Based Continuing Medical Education Using Patient Simulation on Real-World Treatment Selection in Type 2 Diabetes: Retrospective Case-Control Analysis.

Lucero KS, Larkin A, Zakharkin S, Wysham C, Anderson J. Lucero KS, et al. Among authors: anderson j. JMIR Med Educ. 2023 Aug 29;9:e48586. doi: 10.2196/48586. JMIR Med Educ. 2023. PMID: 37642994 Free PMC article.

4

An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Innovations in Insulin: Insulin Glargine U-300.

Anderson JE. Anderson JE. J Fam Pract. 2016 Oct;65(10 Suppl):S23-S28. J Fam Pract. 2016. PMID: 27846339

5

Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.

Blonde L, Anderson JE, Chava P, Dendy JA. Blonde L, et al. Curr Med Res Opin. 2019 May;35(5):793-804. doi: 10.1080/03007995.2018.1541790. Epub 2018 Nov 27. Curr Med Res Opin. 2019. PMID: 30370783 Free article. Review.

6

The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.

Shaefer CF, Anderson J. Shaefer CF, et al. Among authors: anderson j. Postgrad Med. 2016 Jan;128(1):137-44. doi: 10.1080/00325481.2016.1103640. Epub 2015 Nov 7. Postgrad Med. 2016. PMID: 26548422 Review.

7

The Pharmacokinetic Properties of Glucagon-like Peptide-1 Receptor Agonists and Their Mode and Mechanism of Action in Patients with Type 2 Diabetes.

Anderson J. Anderson J. J Fam Pract. 2018 Jun;67(6 suppl):S8-S13. J Fam Pract. 2018. PMID: 29912996 Review.

8

Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes.

Anderson JE. Anderson JE. Diabetes Spectr. 2020 May;33(2):165-174. doi: 10.2337/ds19-0031. Diabetes Spectr. 2020. PMID: 32425454 Free PMC article.

9

Efficacy and Safety of Tirzepatide in Adults With Type 2 Diabetes: A Perspective for Primary Care Providers.

Kushner P, Anderson JE, Simon J, Boye KS, Ranta K, Torcello-Gómez A, Levine JA. Kushner P, et al. Among authors: anderson je. Clin Diabetes. 2023 Spring;41(2):258-272. doi: 10.2337/cd22-0029. Epub 2022 Nov 29. Clin Diabetes. 2023. PMID: 37092144 Free PMC article.

10

Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross-sectional surveys.

Harris SB, Mohammedi K, Bertolini M, Carlyle M, Walker V, Zhou FL, Anderson JE, Seufert J. Harris SB, et al. Among authors: anderson je. Diabetes Obes Metab. 2023 Dec;25(12):3478-3489. doi: 10.1111/dom.15240. Epub 2023 Sep 25. Diabetes Obes Metab. 2023. PMID: 37749746

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,613 results

Search Page

Filters